Trinka E, et al. - Researchers compared the efficacy and safety of once-daily eslicarbazepine acetate with twice-daily (BID) controlled-release carbamazepine (carbamazepine-CR) monotherapy in newly diagnosed focal epilepsy patients. Compared to BID carbamazepine-CR, treatment with eslicarbazepine acetate was noninferior. For adults with newly diagnosed epilepsy and focal onset seizures, eslicarbazepine acetate provided a useful option for first-line monotherapy with its once-daily formulation.